Key facts
- Biologit’s last known valuation is $10.8M (Feb 2025).
- It has raised $3.2M; the latest was Early Stage VC ($2.1M) in Feb 2025.
- Notable investors include Enterprise Ireland, Coyotito Investments, Coyotito Investments Limited, David Shanahan, Gerard Ryan — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Biologit
- ·The full record, as it builds
Funding rounds
No funding rounds for Biologit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biologit
Developer of a scientific literature assessment platform designed to simplify the detection of adverse events from drug development to post-market. The company's platform monitors events in medical literature from global databases to local print publications and provides information about the safety, efficacy, and quality of medicinal products, enabling drug safety professionals to reduce effort and improve accuracy for pharmacovigilance.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2021
- Employees
- 23
- Website
- biologit.com/
- Ownership
- Privately Held (backing)
Biologit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biologit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biologit in its N-PORT filings yet. We sweep new filings monthly.